logo-loader
RNS
viewSynairgen PLC

Synairgen plc - Holding(s) in Company

RNS Number : 9245H
Synairgen plc
27 March 2020
 

Synairgen plc

("Synairgen" or the "Company")

 

Southampton, UK,: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that it was informed on 27 March 2020 that Leonard Licht, a private investor, now holds 9,720,000 ordinary shares of 1 pence each in the capital of the Company, representing 8.88% of the Company's issued share capital.

 

Enquiries:

Synairgen plc

+44 (0) 23 8051 2800

Richard Marsden (Chief Executive Officer)
John Ward (Finance Director)


finnCap - nominated adviser and broker

+44 (0) 20 7220 0500

Geoff Nash / Kate Bannatyne / Charlie Beeson (Corporate Finance)
Alice Lane / Manasa Patil (ECM)


Consilium Strategic Communications - financial media and investor relations adviser

+44 (0) 20 3709 5700

Mary-Jane Elliott / Sue Stuart / Olivia Manser


 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
HOLFLFLEVAIDFII

Quick facts: Synairgen PLC

Price: 44

Market: AIM
Market Cap: £65.75 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Synairgen PLC pleased with further positive data from lead COPD drug

Richard Marsden, chief executive of Synairgen plc (LON:SYN), tells Proactive's Andrew Scott data from the ongoing phase II study of their SNG001 drug suggests it's having the desired effect in boosting the antiviral defences of chronic obstructive pulmonary disease (COPD)...

on 28/6/18